Moderna Stock Surges on Upbeat 2025 Sales Outlook Despite Near-Term Struggles
• Moderna CEO expects sales growth in 2025 based on potential new product launches • Analysts upgraded Moderna stock to "outperform," predicting 5 new products by 2026 • Moderna shares surged 15% on Tuesday amid optimistic outlook • Company struggled in 2023 as COVID vaccine demand dropped • Moderna focusing on revenue and profitability growth over next 2 years